GenFleet Therapeutics (Shanghai) Inc. disclosed that, as of 18 September 2026, it has repurchased an aggregate 872,000 H shares on The Stock Exchange of Hong Kong Limited under its 2026 buyback programme. The volume represents approximately 0.227% of the company’s total issued share capital.
The ongoing repurchase activity is conducted under the general mandate approved by shareholders at the 11 May 2026 annual general meeting. The board retains full discretion over the timing, quantity and pricing of any further buybacks, which will continue to depend on prevailing market conditions.
GenFleet emphasised that there is no assurance regarding the scale or schedule of future repurchases and advised shareholders and potential investors to exercise caution when trading the company’s H shares.
Comments